Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the funding-related notice (Revision: v3.4.1); these changes do not modify the study details, eligibility criteria, or outcomes presented on the page.
    Difference
    0.4%
    Check dated 2026-02-11T14:15:47.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a government funding/operating status notice and updated the page revision tag from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T10:26:23.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    UI/metadata updates were made: added Show glossary, Results First Posted, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0. Removed items include Results First Posted (Estimated), Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.
    Difference
    0.3%
    Check dated 2026-01-28T06:22:43.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision tag updated: v3.3.4 added and v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:38:32.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    A new Locations section includes California as a study site, replacing the prior California Locations entry; the footer now shows revision v3.3.3 and the HHS Vulnerability Disclosure item has been removed.
    Difference
    0.2%
    Check dated 2025-12-23T14:18:53.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Results posted for NCT03007732 on 2025-12-05, with updated Cohort 2 endpoints and expanded safety and efficacy descriptions. The update also includes links to the study protocol and statistical analysis plan.
    Difference
    3%
    Check dated 2025-12-09T00:44:38.000Z thumbnail image

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.